Advertisement

The Complement System

Mechanisms of Action, Biology, and Participation in Dermatological Diseases
  • Irma Gigli
Part of the Comprehensive Immunology book series (COMIMUN, volume 7)

Abstract

Although it is still not possible to integrate completely the various components involved in the inflammatory response, we now have the capability of indicating some of the effector pathways and identifying a number of points of interaction between them. The effector pathway considered in this chapter is the complement system, an essential part of the normal immune response. It consists of a special group of normal serum proteins which on activation interact sequentially in a process of limited proteolysis with the development of active macromolecules and fragments. Appreciation of this complex system has already provided a better understanding of certain pathological processes, the introduction of new therapeutic approaches, and the development of procedures to evaluate disease activity.

Keywords

Systemic Lupus Erythematosus Complement System Chronic Urticaria Classical Pathway Human Complement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abell, E., and Black, M. M., 1974, Immunoglobulin and complement deposits in the skin in inflammatory facial dermatoses—an immunofluorescence study, Br. J. Dermatol. 91 (3): 281.PubMedCrossRefGoogle Scholar
  2. Abramson, N., Alper, C. A., Lachmann, P. J., Rosen, F. S., and Jandl, J. H., 1971, Deficiency of C3 inactivator in man, J. Immunol. 107: 19.PubMedGoogle Scholar
  3. Agnello, V., Koffler, D., Eisenberg, J. W., Winchester, R. J., and Kunkel, H. G., 1971, Clq precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: Characterization of high and low molecular weight types, J. Exp. Med. 134: 228.PubMedGoogle Scholar
  4. Agnello, V., de Bracco, M. M., and Kunkel, H. G., 1972, Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus, J. Immunol. 108: 837.PubMedGoogle Scholar
  5. Alarcon-Segovia, D., and Ramos-Niembro, F., 1976, Association of partial lipodystrophy and Sjogren’s syndrome, Ann. Int. Med. 85: 474.PubMedGoogle Scholar
  6. Alper, C. A., Abramson, N., Johnston, R. B., Jr., Jandl, J. H., and Rosen, F. S., 1970, Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3), N. Engl. J. Med. 282 (7): 349.CrossRefGoogle Scholar
  7. Alper, C. A., Cotten, H. R., Rosen, F. S., Rabson, A. R., Macnab, G. M., and Gear, J. S., 1972a, Homozygous deficiency of C3 in a patient with repeated infections, Lancet 2: 1179.PubMedCrossRefGoogle Scholar
  8. Alper, C. A., Rosen, F. S., and Lachman, P. J., 19726, Inactivation of the third component of complement by an inhibitor in the properdin pathway, Proc. Natl. Acad. Sci. USA 69: 2910.Google Scholar
  9. Alper, C. A., Goodkofsky, I., and Lepow, I. H., 1973a, The relationship of glycine-rich g glycoprotein to factor B in the properdin system and to cobra factor-binding protein of human serum, J. Exp. Med. 137: 424.PubMedCrossRefGoogle Scholar
  10. Alper, C. A., Bloch, K. J., and Rosen, F. S., 1973b, Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3, N. Engl. J. Med. 288: 601.PubMedCrossRefGoogle Scholar
  11. Alpert, E., Isselbacher, K. J., and Schur, P. H., 1971, The pathogenesis of arthritis associated with viral hepatitis: Complement-component studies, N. Engl. J. Med. 285: 185.PubMedCrossRefGoogle Scholar
  12. Arroyave, C. M., and Müller-Eberhard, H. J., 1973, Interactions between human C5, C6 and C7 and their functional significance in complement-dependent cytolysis, J. Immunol. 111: 536.PubMedGoogle Scholar
  13. Arroyave, C. M., and Tan, E. M., 1976, Detection of complement activation by counter immunoelectrophoresis, J. Immunol. Methods 13: 101.PubMedCrossRefGoogle Scholar
  14. Augener, W., Grey, H. M., Cooper, N. R., and Müller-Eberhard, H. J., 1971, The reaction of monomeric and aggregated immunoglobulins with CI, Immunochemistry 8: 1111.CrossRefGoogle Scholar
  15. Baart De la Faille, H., 1975, Erythropoietic protoporphyria: A photodermatosis, thesis defense, Oosthoek, Schelthema and Holkema, Utrecht.Google Scholar
  16. Ballow, M., Ward, G. W., Gershwin, M. E., and Day, N. K., 1975a, C1 bypass complement activation in patients with chronic urticaria and angioedema, Lancet 2: 248.PubMedCrossRefGoogle Scholar
  17. Ballow, M., Ward, G. M., Wilbur, R., and Day, N. K., 1975b, Abnormal serum complement profile in patients with idiopatic urticaria, J. Allergy Clin. Immunol. 55: 105.Google Scholar
  18. Ballow, M., Shira, J. E., Harden, L., Yang, S. Y., and Day, N. K., 1975c, Complete absence of the third component of complement in man, J. Clin. Invest. 56: 703.PubMedCrossRefGoogle Scholar
  19. Bennett, W. M., Bardana, E. J., Wuepper, K., Houghton, D., Border, W. A., Götze, D., and Schreiber, R., 1977, Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis, Am. J. Med. 62: 757.PubMedCrossRefGoogle Scholar
  20. Berrens, L., Jankowski, E., and Jankowski-Berntsen, I., 1976, Complement component profiles in urticaria, dermatitis herpetiformis, and alopecia areata, Br. J. Dermatol. 95 (2): 145.PubMedCrossRefGoogle Scholar
  21. Beutner, E. H., Cherzolski, T. P., Bean, S. F., and Jordan, R. E., (eds.), 1973, Immunopathology of the Skin: Labeled Antibody Studies, Dowden, Hutchinson and Ross, Stroudsburg, Pa.Google Scholar
  22. Beutner, E. H., Jarzabek-Chorzelska, M., Jablonska, S., and Chorzelski, T. P., 1978, Autoimmunity in psoriasis: A complement immunofluorescence study, Arch. Dermatol. Res. 261 (2): 123.PubMedCrossRefGoogle Scholar
  23. Bianco, C., Patrick, R., and Nussenzweig, V., 1970„ Population of lymphocytes bearing a membrane receptor for antigen antibody complexes. 1. Separation and characterization, J. Exp. Med. 132: 702.Google Scholar
  24. Bianco, C., Dukor, P., and Nussenzweig, V., 1971, Follicular localization of antigen: Possible role of lymphocytes bearing a receptor for antigen-antibody complement complexes, in: Morphological and Functional Aspects of Immunity ( K. Lindahl-Kiessling, G. Alm, and G. M. Hanna, Jr., eds.), p. 251, Plenum Press, New York.CrossRefGoogle Scholar
  25. Bladen, H. A., Gewurz, H., and Mergenhaggen, S. E., 1997, Interaction of the complement system with the surface and endotoxic lipopolysaccharide of Veillonella alcalescens, J. Exp. Med. 125: 767.CrossRefGoogle Scholar
  26. Bokisch, V. A., and Muller-Eberhard, H. J., 1970, Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase, J. Clin. Invest. 49: 2427.PubMedCrossRefGoogle Scholar
  27. Bokisch, V. A., Cochrane, C. G., and Müller-Eberhard, H. J., 1969, Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum, J. Exp. Med. 129: 1109.PubMedCrossRefGoogle Scholar
  28. Bokisch, V. A., Top, F. H., Russell, P. K., Dixon, F. J., and Müller-Eberhard, H. J., 1973, The potential role of complement in dengue hemorrhagic shock syndrome, N. Engl. J. Med. 289: 996.PubMedCrossRefGoogle Scholar
  29. Bofotin, C., Morris, S., Tack, B., and Prahl, J., 1977, Purification and structural analysis of the fourth component of human complement, Biochemistry 16: 2008.Google Scholar
  30. Borsos, T., Rapp, H. J., and Mayer, M. M., 1961a, Studies on the second component of complement. I. The reaction between EACI, 4 and C2: Evidence on the single site mechanism of immune hemolysis and determination of C2 on a molecular basis, J. Immunol. 87: 310.Google Scholar
  31. Borsos, T., Rapp, H. J., and Mayer, M. M., 1961b, Studies on the second component of complement. II. The nature of the decay of EAC 142, J. Immunol. 87: 326.Google Scholar
  32. Borsos, T., Dormashkin, R. R., and Humphrey, J. H., 1964, Lesions in erythrocytic membranes caused by immune haemolysis, Nature (London) 4929: 251.CrossRefGoogle Scholar
  33. Boyer, J. T., Gall, E. P., Norman, M. E., Nilsson, U. R., and Zimmerman, T. S., 1975, Hereditary deficiency of the seventh component of complement, J. Clin. Invest. 56: 905.PubMedCrossRefGoogle Scholar
  34. Braun-Falco, O., Maciejewski, W., Schmoeckel, C., and Scherer, R., 1977a, Inynunoelectronmicroscopical demonstration of in vivo bound complement C3 in psoriatic lesions, Arch. Dermatol. Res. 260: 57.PubMedCrossRefGoogle Scholar
  35. Braun-Falco, O., Mannel, C., and Scherer, R., 1977b, Demonstration of circulating soluble immune complexes in the sera of psoriatic patients using the 1251-CI Q deviation test, Hautarzt 28: 658.PubMedGoogle Scholar
  36. Breverman, I. M., 1970, The Angiitides: Skin Signs of Systemic Diseases, p. 199, Saunders, Philadelphia.Google Scholar
  37. Calcott, M. A., and Müller-Eberhard, H. J., 1972, Clq protein of human complement, Biochemistry 11: 3443.PubMedCrossRefGoogle Scholar
  38. Caldwell, R. J., Ruddy, S., Schur, P. H., and Austen, K. F., 1972, CI inhibitor deficiency in lymphosarcoma, Clin. Immunol. Immunopathol. 1: 39.CrossRefGoogle Scholar
  39. Chorzelski, T. P., Jablonska, S., Blaszczyk, M., and Trifthouser, C., 1971, Immunofluorescent studies in the diagnosis of dermatitis herpetiformis and its differentiation from bullous pemphoid, J. Invest. Dermatol. 56: 371.CrossRefGoogle Scholar
  40. Cochrane, C. G., and Müller-Eberhard, H. J., 1998, The derivation of two distinct anaphylatoxin activities from the third and fifth component of human complement, J. Exp. Med. 127: 371.CrossRefGoogle Scholar
  41. Cohen, S. H., Koethe, S. M., et al.,1978, Acquired angioedema associated with rectal carcinoma and its response to danazol therapy, J. Allergy Clin. Immunol. 62:217.Google Scholar
  42. Conradie, J. D., Volauakis, J. E., and Stroud, R. M., 1975, Evidence for a serum inhibitor of Clq, Immunochemistry 12: 967.PubMedCrossRefGoogle Scholar
  43. Cooper, N. R., 1969, Immune adherence by the fourth component of complement, Science 165: 396.PubMedCrossRefGoogle Scholar
  44. Cooper, N. R., 1975a, Enzymatic activity of the second component of complement, Biochemistry 14: 4245.PubMedCrossRefGoogle Scholar
  45. Cooper, N. R., 1975b, Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum, J. Exp. Med. 141: 890.PubMedGoogle Scholar
  46. Cooper, N. R., tenBensel, R., and Kohler, P. F., 1968, Studies of an additional kindred with hereditary deficiency of the second component of human complement (C2) and description of a new method for quantification of C2, J. Immunol. 101: 1176.PubMedGoogle Scholar
  47. Costanzi, J. J., Coltman, C. A., and Donaldson, V. H., 1969, Activation of complement by a monoclonal cry-oglobulin associated with cold urticaria, J. Lab. Clin. Med. 74: 902.PubMedGoogle Scholar
  48. Curd, J. G., Ziccardi, R. J., Kaplan, R., Suridsmo, J. S., Stevenson, D. D., Müller-Eberhard, H. J., and Vaughn, J. H., 1978, The syndrome of Clq deficiency, chronic urticaria, and vasculitis, presented at The Asthma and Allergic Diseases Centers Meeting, NIH, December, Bethesda, Md.Google Scholar
  49. Daha, M. R., Fearon, D. T., and Austen, K. F., 1976, C3 nephritic factor (C3NeF): Stabilization of fluid phase and cell bound alternative pathway convertase, J. Immunol. 116: 1.PubMedGoogle Scholar
  50. Dahl, M. G., and McGibbon, D. H., 1976, Complement in inflammatory acne vulgaris letter, Br. Med. J. 2: 1383.PubMedCrossRefGoogle Scholar
  51. Daniels, C. A., Borsos, T., Rapp, H. J., Snyderman, R., and Notkins, A. L., 1969, Neutralization of sensitized virus by the fourth component of complement, Science 165: 508.PubMedCrossRefGoogle Scholar
  52. Daniels, C. A., Borsos, T., Rapp, H. J., Snyderman, R., and Notkins, A. L., 1970, Neutralization of sensitized virus by purified components of complement, Proc. Natl. Acad. Sci. USA 65: 528.PubMedCrossRefGoogle Scholar
  53. Day, N. K., Geiger, H., Stroud, R., deBracco, M., Man-cado, B., Windhorst, D., and Good, R. A., 1972, Clr deficiency: An inborn error associated with cutaneous and renal disease, J. Clin. Invest. 51: 1102.PubMedCrossRefGoogle Scholar
  54. Day, N. K., Geiger, H., McLean, R., Michael, A., and Good, R. A., 1973, C2 deficiency: Development of lupus erythematosus, J. Clin. Invest. 52: 1601.PubMedCrossRefGoogle Scholar
  55. Day, N. K., L’Esperance, P., and Siniscalco, M., 1975a, Linkage between hereditary C2 deficiency and HL-A, J. Exp. Med. 141: 1464.PubMedCrossRefGoogle Scholar
  56. Day, N. K., Winfield, J. B., Winchester, R. J., Gee, T. S., and Kunkel, H. G., 1975b, Evidence for immune-complexes involving anti-lymphocyte antibodies associated with hypocomplementemia in chronic lymphocytic leukemia, Clin. Res. 23: 410.Google Scholar
  57. Dias Da Silva, W., Eisele, J. W., and Lepow, I. H., 1967, Complement as a mediator of inflammation. III. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C’3, J. Exp. Med. 126: 1027.CrossRefGoogle Scholar
  58. Donaldson, V. H., and Evans, R. R., 1963, A biochemical abnormality in hereditary angioneurotic edema: Absence of serum inhibitor of C’1 esterase, Am. J. Med. 35: 37.PubMedCrossRefGoogle Scholar
  59. Donaldson, V. H., Rosen, F. S., and Bing, D. H., 1977, Role of the second component of complement and plasmin in kinin release in hereditary angioneurotic edema, Clin. Res. 25: 520A.Google Scholar
  60. Dukor, P., and Hartmann, K. H., 1973, Bound C3 as the second signal for B-cell activation, Cell. Immunol. 7: 349.PubMedCrossRefGoogle Scholar
  61. Eden, A., Miller, G. W., and Nussenzweig, V., 1973, Human lymphocytes bear membrane receptors for C3b and C3d, J. Clin. Invest. 52: 3239.PubMedCrossRefGoogle Scholar
  62. Ehlenberger, A. G., and Nussenzweig, V., 1975, Synergy between receptors for FC and C3 in the induction of phagocytosis by human monocytes and neutrophils, Fed. Proc. 34: 854.Google Scholar
  63. Eisenger, A. J., Shortland, J. R., and Moorhead, P. J., 1972, Renal disease in partial lipodystrophy, Q. J. Med. 41: 343.Google Scholar
  64. Epstein, J. H., Tuffanelli, D. L., and Epstein, W. L., 1973, Cutaneous changes in the porphyrias—A microscopic study, Arch. Dermatol. 107: 684.CrossRefGoogle Scholar
  65. Fearon, D. T., 1978, Regulation by membrane sialic acid of ß1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway, Proc. Natl. Acad. Sci. USA 75: 1971.Google Scholar
  66. Fearon, D. T., and Austen, K. F., 1975a, Properdin: Building to C3b and stabilization of the C3b dependent C3 convertase, J. Exp. Med. 142: 856.PubMedCrossRefGoogle Scholar
  67. Fearon, D. T., and Austen, K. F., 1975b, Properdin: Initiation of alternative complement pathway, Proc. Natl. Acad. Sci. USA 72: 3220.PubMedCrossRefGoogle Scholar
  68. Fearon, D. T., and Austen, K. F., 1977, Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms, Proc. Natl. Acad. Sci. USA 74: 1683.PubMedCrossRefGoogle Scholar
  69. Fearon, D. T., Austen, K. F., and Ruddy, S., 1973, Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement, J. Exp. Med. 138: 1305.PubMedCrossRefGoogle Scholar
  70. Fearon, D. T., Daha, M. R., Weiler, J. M., and Austen, K. F., 1976, The natural modulation of the amplification phase of complement activation, Transplant. Rev. 32: 12.PubMedGoogle Scholar
  71. Fearon, 1978, Activation of the alternative complement pathway by Escherichia coli: Resistance of bound C3b to inactivation by C3bINA and ß1H, J. Immunol. 120: 1772.Google Scholar
  72. Feig, P. U., Soter, N. A., Yager, H. M., Caplan, L., and Rosen, S., 1976, Vasculitis with urticaria, hypocomplementemia, and multiple system involvement, J. Am. Med. Assoc. 236: 2065.CrossRefGoogle Scholar
  73. Fernandez, N. O., Henson, P. M., Otani, A., and Hugli, T. E., 1978, Chemotactic response to human C3a and C5a anaphylatoxins. 1. Evaluation of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions, J. Immunol. 120: 109.PubMedGoogle Scholar
  74. Friend, P., Repine, J. E., Kim, Y., Clawson, C. C., and Michael, A. F., 1975, Deficiency of the second component of complement (C2) with chronic vasculitis, Ann. Int. Med. 83: 813.PubMedGoogle Scholar
  75. Fu, B. S. M., Kunkel, H. G., Brusman, H. P., Allen, F. H., Jr., and Fotino, M., 1974, Evidence for linkage between HL-A histocompatibility genes and those involved in the synthesis of the second component of complement, J. Exp. Med. 140: 1108.PubMedCrossRefGoogle Scholar
  76. Fujita, T., Gigli, I., and Nussenzweig, V., 1978, Human C4-binding protein. H. Role in proteolysis of C4b by C3b-inactivator, J. Exp. Med. 148: 1044.PubMedCrossRefGoogle Scholar
  77. Geha, R. S., and Alk, K. F., 1976, Skin lesions, angioedema, eosinophilia, and hypocomplementemia, J. Pediatr. 89: 724.PubMedCrossRefGoogle Scholar
  78. Gelfand, E. W., Clarkson, J. E., and Minta, J. O., 1975, Selective deficiency of the second component of complement in a patient with anaphylactoid purpura, Clin. Immunol. Immunopathol. 4: 269.PubMedCrossRefGoogle Scholar
  79. Gelfand, J. A., Sherins, R. J., Ailing, D. W., and Frank, M. M., 1976, Treatment of hereditary angioedema with Danazol: Reversal of clinical and biochemical abnormalities, N. Engl. J. Med. 295: 1444.PubMedCrossRefGoogle Scholar
  80. Gellis, S., Green, S., and Walker, D., 1958, Chronic renal disease in children with lipodystrophy, Am. J. Dis. Child. 96: 605.Google Scholar
  81. Gewurz, A., and Lint, T. F., 1978, Homozygous C2 deficiency with fulminant lupus erythematosus: Severe nephritis via the alternative complement pathway, Arthritis Rheum. 21 (1): 28.PubMedCrossRefGoogle Scholar
  82. Gewurz, H., Pickering, R. J., Mergenhagen, S. E., and Good, R. A., 1966, The complement profile in acute glomerulonephritis, systemic lupus erythematosus, and hypocomplementemic glomerulonephritis, Int. Arch. Allergy Appl. Immunol. 34: 556.CrossRefGoogle Scholar
  83. Gewurz, H., Pickering, R. J., Snyderman, R., Lichtenstein, L. M., and Good, R. A., 1970, Interaction of the complement system with endotoxin lipopolysaccharide in immunoglobulin-deficient sera, J.. Exp. Med. 131: 817.PubMedCrossRefGoogle Scholar
  84. Ghebrehiwet, B., and Müller-Eberhard, H. J., 1979, C3e: An acidic fragment of human C3 with leukocytosis-inducing activity, J. Immunol. 123: 616.PubMedGoogle Scholar
  85. Gigli, I., and Austen, K. F., 1969, Fluid phase destruction of C4 by Cl: Its enhancement and inhibition by homologous and heterologous C4, J. Exp. Med. 129: 679.PubMedCrossRefGoogle Scholar
  86. Gigli, I., and Nelson, R. A., 1968, Complement dependent immune phagocytosis. 1. Requirement for CI, C4, C2, and C3, Exp. Cell Res. 51: 45.PubMedCrossRefGoogle Scholar
  87. Gigli, I., Ruddy, S., and Austen, K. F., 1968, The stoichiometric measurement of the serum inhibitor of the first component of complement by inhibition of immune hemolysis, J. Immunol. 100: 1154.PubMedGoogle Scholar
  88. Gigli, I., Mason, J. W., Colman, R. W., and Austen, K. F., 1970, Interaction of plasma kallikrein with the CT inhibitor, J. Immunol. 104: 574.PubMedGoogle Scholar
  89. Gigli, I., Schothorst, A., Soter, N. A., and Pathek, M., 1974, Photoinhibition of the complement system in erythropoietic protoporphyria, Clin. Res. 22: 418a.Google Scholar
  90. Gigli, I., Koethe, S., and Austen, K. F., 1975, Participation of an early component of complement and Hage-man factor in C3 destruction by zymosan, Clin. Immunol. Immunopathol. 4: 189.PubMedCrossRefGoogle Scholar
  91. Gigli, I., Porter, R., and Sim, R. B., 1976, The unactivated form of the first component of human complement, Cl, Biochem. J. 157: 541.PubMedGoogle Scholar
  92. Gigli, I., Von Zabern, I., and Porter, R. R., 1977, The isolation and structure of C4, the fourth component of human complement, Biochem. J. 165: 439.PubMedGoogle Scholar
  93. Gigli, I., Fujita, T., and Nussenzweig, V., 1979, Modulation of the classical pathway C3 convertase by the plasma proteins C4-binding protein and C3b inactiva-tor, Proc. Natl. Acad. Sci. USA 76: 6596.PubMedCrossRefGoogle Scholar
  94. Giraldo, G., DeGos, L., Beth, E., Sasportes, M., Mar-celli, A., Harbi, R., and Day, N. K., 1977, C8 deficiency in a family with xeroderma pigmentosum. Lack of linkage to the HLA region, Clin. Immunol. Immunopathol. 8: 377.PubMedCrossRefGoogle Scholar
  95. Goldman, J. N., Ruddy, S., and Austen, K. F., 1972, Reaction mechanisms of nascent C567 (reactive lysis). I. Reaction characteristics for production of EC567 and lysis by C8 and C9, J. Immunol. 109: 353.PubMedGoogle Scholar
  96. Goldstein, I. M., and Gigli, I., 1980, Recurrent meningococcal meningitis in a patient with complete absence of the sixth component of complement, ms. submitted for publication.Google Scholar
  97. Goldstein, I. M., Kaplan, H. B., Radin, A., and Frosch, M., 1976, Independent effects of IgG and complement upon human polymorphonuclear leukocyte function, J. Immunol. 117: 1282.PubMedGoogle Scholar
  98. Götze, O., and Müller-Eberhard, H. J., 1976, The alternative pathway of complement activation, Adv. Immmunol. 24: 1.CrossRefGoogle Scholar
  99. Gower, R., Sausker, W., Kohler, P., Thorne, G. G., and McIntosh, R., 1978, Small vessel vasculitis caused by hepatitis B virus immune complexes, J. Allergy Clin. Immunol. 62: 222.PubMedCrossRefGoogle Scholar
  100. Granerus, G., Hallberg, L., Laurell, A. B., and Wetterguist, H., 1967, Studies on the histamine metabolism and the complement system in hereditary angioneurotic edema, Acta Med. Scand. 182: 11.PubMedCrossRefGoogle Scholar
  101. Hauptmann, G., Groshans, E., and Heid, E., 1974, Lupus erythematoux aigus et deficits hereditaires en complement. A propos d’un cas par deficit complet en C4, Ann. Dermatol. 101: 479.Google Scholar
  102. Huber, H., Polley, M. J., Linscott, W. D., Fudenberg, H. H., and Müller-Eberhard, H. J., 1968, Human monocytes: Distinct receptor sites for the third component of complement and for immunoglobulin G, Science 162: 1281.PubMedCrossRefGoogle Scholar
  103. Hunsicker, L. G., Ruddy, S., Carpenter, C. B., Schur, P. H., Merrill, J. P., Müller-Eberhard, H. J., and Austen, F., 1972, Metabolism of the third complement (C3) in nephritis, N. Engl. J. Med. 287: 835.PubMedCrossRefGoogle Scholar
  104. Hunsicker, L. G., Ruddy, S., and Austen, K. F., 1973, Alternate complement pathway: Factors involved in cobra venom factor (CVF) activation of the third component of complement, J. Immunol. 110: 128.PubMedGoogle Scholar
  105. Ishizaka, T., Ishizaka, K., Borsos, T., and Rapp, H., 1966, Cl fixation by human isoagglutinin: Fixation of CI by YG and YM but not YA antibody, J. Immunol. 97: 716.PubMedGoogle Scholar
  106. Jablonska, S., Chorzelski, P., Jarzabek-Chorzelska, M., and Beutner, E. H., 1976, Immunofluorescent findings in psoriasis of the scalp, in: Biology and Disease of the Hair ( K. Toda, ed.), p. 309, University Park Press, Baltimore.Google Scholar
  107. Jablonska, S., Chorzelski, T. P., Beutner, E. H., Maciejowska, E., Abek-Chorzelska, X., and Esa, G., 1978, Autoimmunity in psoriasis. Relation of disease activity and forms of psoriasis to immunofluorescence findings, Arch. Dermatol. Res. 261: 135.PubMedCrossRefGoogle Scholar
  108. Jamison, T. H., Cooper, N. M., and Epstein, W. V., 1978, Lichen planus and discoid lupus erythematosus: Overlap syndrome associated with cryoglobulinemia and hypocomplementemia, Arch. Dermatol. 114: 1039.PubMedCrossRefGoogle Scholar
  109. Jasin, H. E., 1977, Absence of the eighth component of complement in association with systemic lupus erythematosus-like disease, J. Clin. Invest. 60: 709.PubMedCrossRefGoogle Scholar
  110. Jensen, J., 1967, Anaphylatoxin in its relation to the complement system, Science 155: 1122.PubMedCrossRefGoogle Scholar
  111. Jordan, R. E., and Provost, T. T., 1978, Bullous diseases of the skin, in: Immunological Diseases, Vol. 2 (M. Sauster, ed.), Little, Brown, New York.Google Scholar
  112. Jordan, R. E., Day, N. K., Sams, W. M., and Good, R. A., 1973a, The complement system in bullous pemphigoid. I. Complement and component level in sera and blister fluid, J. Clin. Invest. 52: 1207.CrossRefGoogle Scholar
  113. Jordan, R. E., Day, N. K., Luckasen, J. R., and Good, R. A., 1973b, Complement activation in pemphigus vulgaris blister fluid, Clin. Exp. Immunol. 15: 53.Google Scholar
  114. Jordan, R. E., McDuffe, F. C., Good, R. A., and Day, N. K., 1974, Diffuse normolipaemic plane xanthomatosis, Clin. Exp. Immunol. 18: 407.Google Scholar
  115. Kagan, L. J., 1964, Some biochemical and physical properties of the human permeability globulins, Br. J. Exp. Pathol. 45: 604.Google Scholar
  116. Kerr, M. A., and Porter, R. R., 1978, The purification and properties of the second component of human complement, Biochem. J. 171: 99.PubMedGoogle Scholar
  117. Kikindjanin, V., and Milakov, J., 1976, Serum immunoglobulin and complement levels in patients with psoriasis vulgaris, Allerg. Immunol. 22 (2): 143.Google Scholar
  118. Kim, Y., Friend, P. S., Dresner, I. G., Yunis, E. J., and Michael, A. F., 1977, Inherited deficiency of the second component of complement (C2) with membranoproliferative glomerulonephritis, Am. J. Med. 62: 765.PubMedCrossRefGoogle Scholar
  119. Klemperer, M. R., Woodworth, H. C., Rosen, F. S., and Austen, K. F., 1966, Hereditary deficiency of the second component of complement (C2) in man, J. Clin. Invest. 45: 880.PubMedCrossRefGoogle Scholar
  120. Kohler, P. F., 1973, Clinical immune complex disease: Manifestations in systemic lupus erythematosus and hepatitis B virus infection, Medicine (Baltimore) 52: 419.CrossRefGoogle Scholar
  121. Kohler, P. F., Percy, J., Wookrow, M. C., and Smyth, C. J., 1974, Hereditary angioedema and familiar lupus erythematosus in identical twin boys, Am. J. Med. 56: 406.PubMedCrossRefGoogle Scholar
  122. Kolb, W. P., Haxby, J. A., Arroyave, C. M., and Muller-Eberhard, H. J., 1972, Molecular analysis of the membrane attack mechanism of complement, J. Exp. Med. 135: 549.PubMedCrossRefGoogle Scholar
  123. Lachmann, P. J., and Müller-Eberhard, H. J., 1968, The demonstration in human serum of conglutinogen-activity factor and its effect on the third component of complement, J. Immunol. 100: 691.PubMedGoogle Scholar
  124. Lachmann, P. J., and Thompson, R. A., 1970, Reactive lysig: The complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C5b and the participation of C8 and C9, J. Exp. Med. 131: 643.PubMedCrossRefGoogle Scholar
  125. Lachmann, P. J., Hobart, M. J., and Woo, P., 1978, Combined genetic deficiency of C6 and C7 in man, Clin. Exp. Immunol. 33: 193.PubMedGoogle Scholar
  126. Laurell, C. B., 1966, Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies, Anal. Biochem. 15: 45.PubMedCrossRefGoogle Scholar
  127. Laurell, C. B., Johnson, U., Martensson, U., and Sjohlm, A. G., 1978, Formation of complexes composed of CT, CTs s and CTinactivator inactivator in human serum on activation of Cl, Acta Pathol. Microbiol. Scand. 86C: 299.Google Scholar
  128. Lay, W. H., and Nussenzweig, V., 1968, Receptors for complement on leukocytes, J. Exp. Med. 128:991.PubMedCrossRefGoogle Scholar
  129. Lazarus, G. S., Yost, F. J., and Thomas, C. A., 1977, Polymorphonuclear leukocytes: Possible mechanism of accumulation in psoriasis, Science 198: 1162.PubMedCrossRefGoogle Scholar
  130. Leddy, J. P., Frank, M. M., Gaither, T., Baum, J., and Klemperer, M. R., 1974, Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic and family studies, J. Clin. Invest. 53: 544.PubMedCrossRefGoogle Scholar
  131. Leddy, J. P., Griggs, R. C., Klemperer, M. R., and Frank, M. M., 1975, Hereditary complement (C2) deficiency with dermatomyositis, Am. J. Med. 58: 83.PubMedCrossRefGoogle Scholar
  132. Lehner, T., 1968, Autoimmunity in oral diseases, with special reference to recurrent oral ulceration, Proc. R. Soc. Med. 61: 515.PubMedGoogle Scholar
  133. Lepow, I. H., Ratnoff, O. J., and Pillemer, L., 1956, Elution of an esterase from antigen-antibody aggregates treated with human complement, Proc. Soc. Exp. Biol. Med. 92: 32.PubMedGoogle Scholar
  134. Lepow, I. H., Noff, G. B., Todd, E., Pensky, J., and Hinz, C. F., Jr., 1963, Chromatographic resolution of the first component of human complement into three activities, J. Exp. Med. 117: 983.PubMedCrossRefGoogle Scholar
  135. Lepow, I. H., Dias da Silva, W., and Eisele, J. W., 1968, Nature and biological properties of human anaphylatoxin, in: Biochemistry of the Acute Allergic Reactions ( K. F. Austen and E. L. Becker, eds.), Davis, Philadelphia.Google Scholar
  136. Lepow, I. H., Dias da Silva, W., and Patrick, R. A., 1969, Biologically active cleavage products of components of complement, in: Cellular and Humoral Mechanisms in Anaphylaxis and Allergy ( H. Z. Movat, ed.), p. 237, Karger, Basel.Google Scholar
  137. Lepow, I. H., Willms-Kretschmer, K., and Patrick, R. A., 1970, Gross and ultrastructural observations on lesions produced by intradermal injection of human C3a in man, Am. J. Pathol. 61: 13.PubMedGoogle Scholar
  138. Levinsky, R. J., and Lehner, T., 1978, Immune complexes in oral ulcerations and Behçet’s syndrome, Clin. Exp. Immunol. 32: 190.Google Scholar
  139. Levy, L. R., and Lepow, I. H., 1959, Assay and properties of serum inhibitor of C1-esterase, Proc. Soc. Exp. Biol. Med. 101: 608.PubMedGoogle Scholar
  140. Lim, D., Gewurz, A., Ghaze, M., Lint, T. F., Sephari, B., and Gewurz, H., 1976, Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis, J. Pediatr. 89: 42.PubMedCrossRefGoogle Scholar
  141. Lint, T. F., Behrends, C. L., and Gewurz, H., 1977, Serum lipoproteins and C567-INH activity, J. Immunol. 119: 883.PubMedGoogle Scholar
  142. Louie, J. S., and Glovsky, M., 1975, Complement determinations in the synovial fluid and serum of a patient with erythema nodosum leprosum, Int. J. Lepr. 43 (3): 252.Google Scholar
  143. Mahler, F., Intaglietta, M., Hugli, T. E., and Johnson, A. R., 1975, Influences of C3a anaphylatoxin compared to other vasoactive agents on the microcirculation of the rabbit omentum, Microvasc. Res. 9: 345.PubMedCrossRefGoogle Scholar
  144. Mancini, G., Carbonara, A. O., and Heremans, J. F., 1%5, Immunochemical quantitation of antigens by single radial immunodiffusion, Immunochemistry 2: 235.Google Scholar
  145. Marcus, R. L., Shin, H. S., and Mayer, M. M., 1971, An alternate complement pathway: C3 cleaving activity, not due to C4,C2a, on endotoxin lipopolysaccharide after treatment with guinea pig serum: Relation to proper-din complement components, Proc. Natl. Acad. Sci. USA 68: 1351.PubMedCrossRefGoogle Scholar
  146. Marder, R. J., Rent, R., Choi, E. J., and Gewurz, H., 1976, Selective Clq deficiency associated with urticaria-like lesions and cutaneous vasculitis, Am. J. Med. 61: 560.PubMedCrossRefGoogle Scholar
  147. Marshall, D. A., Nesbitt, L. T., and Biundo, J. J., 1974, Serum complement related to skin lesions of systemic lupus erythematosus, South. Med. J. 67: 1275.PubMedCrossRefGoogle Scholar
  148. May, J. E., Green, I., and Frank, M. M., 1972, The alternate complement pathway in cell damage: Antibody mediated cytolysis of erythrocytes and nucleated cells, J. Immunol. 109: 595.PubMedGoogle Scholar
  149. Mayer, M. M., 1964, Complement and complement fixation, in: Experimental Immunochemistry ( E. A. Kabat and M. M. Mayer, eds.), p. 133, Thomas, Springfield, Ill.Google Scholar
  150. Mayer, M. M., 1972, Mechanism of cytolysis by complement, Proc. Natl. Acad. Sci. USA 69: 2954.PubMedCrossRefGoogle Scholar
  151. McConnell, I., Klein, G., Lint, T. F., and Lachmann, P. J., 1978, Activation of alternative complement pathway by human B-cell lymphoma lines is associated with Epstein-Barr transformation of cells, Eur. J. Immunol. 8: 453.PubMedCrossRefGoogle Scholar
  152. McDuffie, F. C., Sams, W. M., Jr., Maldonado, J. E., Andreini, P. H., Conn, D. L., and Samayoa, E. A., 1973, Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome, Mayo Clin. Proc. 48: 340.PubMedGoogle Scholar
  153. McLeod, B., Baker, P., and Gewurz, H., 1975, Studies on the inhibition of C56 initiated lysis (reactive lysis). III. Characterization of the inhibitor activity C567-INH and its mode of action, Immunology 28: 133.PubMedGoogle Scholar
  154. Medicus, R. G., Schreiber, R. D., Götze, O., and Müller-Eberhard, H. J., 1976, A molecular concept of the properdin pathway, Proc. Natl. Acad. Sci. USA 73: 612.PubMedCrossRefGoogle Scholar
  155. Miescher, P. A., Paronetto, F., and Kollier, D., 1965, Immunofluorescent studies in human vasculitis, in: Immunopathology IV International Symposium ( P. Grabar and P. Miescher, eds.), p. 446, Grune and Stratton, New York.Google Scholar
  156. Milgrom, R., Curd, J. G., Stevenson, D. D., Mathison, D. A., and Vaughn, J. H., 1978, Iodide sensitivity in patients with chronic idiopathic urticaria or systemic lupus erythematosus, presented at the Asthma and Allergic Diseases Center, December, NIH, Bethesda, Md.Google Scholar
  157. Miller, G. W., and Nussenzweig, V., 1974, Complement as regulator of interactions between immune-complexes and cell membranes, J. Immunol. 113: 464.PubMedGoogle Scholar
  158. Miller, M. E., and Nilsson, U. R., 1970, A familial deficiency of the phagocytosis-enhancing activity of serum related to a dysfunction of the fifth component of complement (C5), N. Engl. J. Med. 282 (7): 354.PubMedCrossRefGoogle Scholar
  159. Miller, M. E., and Nilsson, U. R., 1974, A major role of the fifth component of complement in the opsonization of yeast particles. Partial dichotomy of function and immunochemical measurement, Clin. Immunol. Immunopathol. 2: 246.PubMedCrossRefGoogle Scholar
  160. Mills, B. J., and Cooper, N. R., 1978, Antibody-independent neutralization of vesicular stomatitis virus by human complement, J. Immunol. 121: 1549.PubMedGoogle Scholar
  161. Minta, J. O., and Lepow, I. H., 1974, Physical and chemical studies of human properdin purified by elution from zymosan and affinity chromatography, Immunochemistry 11: 361.PubMedCrossRefGoogle Scholar
  162. Moncada, B., Day, N. K. B., Good, R. A., and Windhorst, D. B., 1972, Lupus-erythematosus-like syndrome with a familial defect of complement, N. Engl. J. Med. 286: 689.PubMedCrossRefGoogle Scholar
  163. Montovani, B., 1975, Different roles of IgG and complement receptors in phagocytosis by polymorphonuclear leukocytes, J. Immunol. 115: 15.Google Scholar
  164. Montovani, B., Rabinovitch, M., and Nussenzweig, V., 1972, Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites from complement (C3) and for immunoglobulin (IgG), J. Exp. Med. 135: 780.CrossRefGoogle Scholar
  165. Müller-Eberhard, H. J., 1975, Complement, Annu. Rev. Biochem. 44: 697.PubMedCrossRefGoogle Scholar
  166. Müller-Eberhard, H. J., and Biro, E., 1967, Isolation and description of the fourth component of human complement, J. Exp. Med. 118: 447.CrossRefGoogle Scholar
  167. Müller-Eberhard, H. J., and Goetz, O., 1972, C3 proactivator convertase and its mode of action, J. Exp. Med. 135: 1003.PubMedCrossRefGoogle Scholar
  168. Müller-Eberhard, H. J., and Lepow, I. H., 1965, Cl esterase effect on activity and physicochemical properties of the fourth component of complement, J. Exp. Med. 121: 819.CrossRefGoogle Scholar
  169. Müller-Eberhard, H. J., Dalmasso, A. P., and Calcott, M. A., 1966, The reaction mechanism of 1.3 IC globulin in immune hemolysis, J. Exp. Med. 123: 33.CrossRefGoogle Scholar
  170. Müller-Eberhard, H. J., Polley, M. H., and Calcott, M. A., 1967, Formation and functional significance of a molecular complex derived from the second and fourth components of human complement, J. Exp. Med. 125: 359.PubMedCrossRefGoogle Scholar
  171. Naff, G. B., and Ratnoff, O. D., 1968, The enzymatic nature of CIr. Conversion of CI to Cl esterase and digestion of amino acid esters by Clr, J. Exp. Med. 128: 571.PubMedCrossRefGoogle Scholar
  172. Naff, G. B., Pensky, J., and Lepow, I. H., 1964, The macromolecular nature of the first component of human complement, J. Exp. Med. 119: 593.PubMedCrossRefGoogle Scholar
  173. Nagasawa, S., and Stroud, R. M., 1977, Cleavage of C2 by C 1 s into the antigenically distinct fragments C2a and C2, Proc. Natl. Acad. Sci. USA 74: 2998.PubMedCrossRefGoogle Scholar
  174. Nelson, R. A., 1953, The immune adherence phenomenon: An immunologically specific reaction between microorganisms and erythrocytes leading to the enhancement of phagocytosis, Science 118: 733.PubMedCrossRefGoogle Scholar
  175. Newman, S. L., Vogler, L. B., Feigin, R. D., and Johnston, R. B., Jr., 1978, Recurrent septicemia associated with congenital deficiency of C2 and partial deficiency of factor B and the alternative complement pathway, N. Engl. J. Med. 299 (6): 290.PubMedCrossRefGoogle Scholar
  176. Nilsson, U. R., and Mapes, J., 1973, Polyacrylamide gel electrophoresis (PAGE) of reduced and dissociated C3 and C5: Studies of the polypeptide chains (PPC) subunits and their modifications by trypsin and C42–C423, J. Immunol. 111: 293.Google Scholar
  177. Oberling, F., Hauptmann, G., Lang, J. M., North, M. L., Mayer, G., and Lachman, P., 1976, Acquired C-1-inhibitor deficiency in lymphoproliferative disease with serum immunoglobulin abnormality, Blut 32: 195.PubMedCrossRefGoogle Scholar
  178. Ochs, H. D., Rosenfeld, S. I., Thomas, D. E., Giblett, E., Alper, C. A., Dupont, B., Schaller, J. G., Gilliland, B. C., Hansen, J. A., and Wedgwood, R. J., 1977, Linkage between the gene (or genes) controlling synthesis of the fourth component of complement and the major histocompatibility complex, N. Engl. J. Med. 296: 470.PubMedCrossRefGoogle Scholar
  179. Ochs, H. D., Jackson, C. G., Frank, M. M., Hosea, S. W., and Wedgwood, R. J., 1978, Antibody responses to a T cell dependent antigen in C4 deficiency, J. Immunol. 120: 1789.Google Scholar
  180. Oishi, M., Takano, M., Miyachi, K., Ichikawa, Y., and Homma, M., 1976, A case of unusual SLE-related syndrome characterized by erythema multiforme, angioneurotic edema and marked hypocomplementemia, Int. Arch. Allergy Appl. Immunol. 50: 463.PubMedCrossRefGoogle Scholar
  181. Onion, D. K., Crumpacker, C. S., and Gilliland, B. C., 1971, Arthritis of hepatitis associated with Australia antigen, Ann. Intern. Med. 75: 29.PubMedGoogle Scholar
  182. Osier, A. G., Randall, H. G., Hill, B. M., and Ovary, Z., 1959a, Some relationship between complement, passive cutaneous anaphylaxis and anaphylatoxin, in: The Mechanics of Hypersensitivity ( J. H. Shaffer, ed.), p. 281, Little, Brown, Boston.Google Scholar
  183. Oster, A. G., Randall, H. G., Hill, B. M., and Ovary, Z., 1959b, Studies on the mechanism of hypersensitivity phenomena. III. The participation of complement in the formation of anaphylatoxin, J. Exp. Med. 110: 311.CrossRefGoogle Scholar
  184. Osier, A. G., Oliveria, B., Shin, H. S., and Sandberg, A. L., 1969, The fixation of guinea pig complement by Y 1, Y2 immunoglobulins, J. Immunol. 102: 269.Google Scholar
  185. Osier, W., 1888, Hereditary angio-neurotic edema, Am. J. Med. Sci. 95: 362.CrossRefGoogle Scholar
  186. Osofsky, S. G., Thompson, B. H., Lint, T. F., and Gewurz, H., 1977, Hereditary deficiency of the third component of complement in a child with fever, skin rash, and arthralgias: Response to transfusion of whole blood, J. Pediatr. 90: 180.PubMedCrossRefGoogle Scholar
  187. Osterland, C. K., Espinoza, L., Parker, L. P., and Schur, P. H., 1975, Inherited C2 deficiency and systemic lupus erythematosus: Studies on a family, Ann. Int. Med. 82: 323.PubMedGoogle Scholar
  188. Pangburn, M. K., and Müller-Eberhard, H. J., 1978, Complement C3 convertase: Cell surface restriction of 131H control and generation of restriction on neuraminidase-treated cells, Proc. Natl. Acad, Sci. USA 75: 2416.CrossRefGoogle Scholar
  189. Pangburn, M. K., Schreiber, R. D., and Müller-Eberhard, H. J., 1977, Human complement C3b inactivator: Isolation, characterization, and demonstration of an absolute requirement for the serum protein ß 1H for cleavage of C3b and C4b in solution, J. Exp. Med. 146: 257.PubMedCrossRefGoogle Scholar
  190. Pensky, J., and Schwick, H. G., 1969, Human serum inhibitor of C’1 esterase: Identity, with a2-neuraminoglycoprotein, Science 163: 698.PubMedCrossRefGoogle Scholar
  191. Pensky, J., Levy, L. R., and Lepow, I. H., 1961, Partial purification of a serum inhibitor of C’ 1-esterase, J. Biol. Chem. 236: 1674.PubMedGoogle Scholar
  192. Pepys, M. B., 1974, Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus dependent and thymus independent antibody response, J. Exp. Med. 140: 126.PubMedCrossRefGoogle Scholar
  193. Peters, D. K., Williams, D. G., Charlesworth, J. A., Boulton-Jones, J. M., Sissons, J. G. P., Evans, D. J., Kourilsky, O., and Morel-Maroger, L., 1973, Mesangiocapillary nephritis, partial lipodystrophy and hypocomplementaemia, Lancet 2: 535.PubMedCrossRefGoogle Scholar
  194. Petersen, B. H., Graham, J. A., and Brooks, G. F., 1976, Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity, J. Clin. Invest. 57: 283.PubMedCrossRefGoogle Scholar
  195. Pfaffenbach, G., Lamm, M., and Gigli, I., 1978, Activation of complement by mouse IgA immune-complexes, Fed. Proc. 37: 1377.Google Scholar
  196. Pickering, R. J., Naff, G. B., Stroud, R. M., Good, R. A., and Gewurz, H., 1970, Deficiency of C1r in human serum: Effects on the structure and function of macro-molecular C 1, J. Exp. Med. 131: 803.PubMedCrossRefGoogle Scholar
  197. Pickering, R. J., Michael, A. F., Jr., Herdman, R. C., Good, R. A., and Gewurz, H., 1971, The complement system in chronic glomerulonephritis: Three newly associated aberrations, J. Pediatr. 78: 30–43.PubMedCrossRefGoogle Scholar
  198. Pillemer, L., and Ecker, E. E., 1941, Anticomplementary factors in yeasts, J. Biol. Chem. 137: 139.Google Scholar
  199. Pillemer, L., Blum, L., Lepow, I. H., Ross, O. A., Todd, E. W., and Wardlaw, A. C., 1954, The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena, Science 120: 279.PubMedCrossRefGoogle Scholar
  200. Pincus, S., Bianco, C., and Nussenzweig, V., 1972, Increased proportion of complement receptor lymphocytes in the peripheral blood of patients with chronic lymphatic leukemia, Blood 40: 303.PubMedGoogle Scholar
  201. Platts-Mills, T. A. E., and Ishizaka, K., 1974, Activation of the alternate pathway of human complement by rabbit cells, J. Immunol. 113: 348.PubMedGoogle Scholar
  202. Podack, E. R., Kolb, W. P., and Müller-Eberhard, H. J., 1978, The C5b-6 complex: Formation, isolation and inhibition of its activity by lipoprotein and the S protein of human serum, J. Immunol. 120: 1841.PubMedGoogle Scholar
  203. Polley, M. J., and Müller-Eberhard, H. J., 1968, The second component of human complement: Its isolation, fragmentation by Cl-esterase and incorporation into C3 convertase, J. Exp. Med. 128: 533.PubMedCrossRefGoogle Scholar
  204. Pondman, K. W., Stoop, J. W., Cormane, R. H., and Hannema, A. J., 1968, Abnormal C1 in a patient with systemic lupus erythematosus, J. Immunol. 101: 811.Google Scholar
  205. Poskitt, T.R., Fortwengler, H.P., Jr., and Lunskis, B.J., 1973, Activation of the alternate complement pathway by autologous red cell stroma, J. Exp. Med. 138: 715.PubMedCrossRefGoogle Scholar
  206. Provost, T. T., and Tomasi, T. B., Jr., 1974, Evidence for the activation of complement via the alternate pathway in skin diseases. H. Dermatitis herpetiformis, Clin. Immunol. Immunopathol. 3: 178.PubMedCrossRefGoogle Scholar
  207. Ratnoff, O. D., and Naff, G. B., 1967, The conversion of C’ 1 s to C’ 1 esterase by plasmin and trypsin, J. Exp. Med. 125: 337.PubMedCrossRefGoogle Scholar
  208. Ratnoff, O. D., Pensky, J., Ogston, D., and Naff, G. B., 1969, The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the Clr of complement by serum Cl esterase inhibitor, J. Exp. Med. 129: 315.PubMedCrossRefGoogle Scholar
  209. Reid, K. B. M., 1971, Complement fixation by the F(ab’)2 fragment of pepsin treated antibody, Immunology 20: 649.PubMedGoogle Scholar
  210. Reid, K. B. M., 1974, A collagen-like amino acid sequence in a polypeptide chain of human Clq (a subcomponent of the first component of complement), Biochem. J. 141: 189.PubMedGoogle Scholar
  211. Reid, K. B. M., and Porter, R. R., 1975, The structure and mechanism of activation of the first component of complement, Contemp. Top. Mol. Immunol. 4: 1.PubMedGoogle Scholar
  212. Reid, K. B. M., Lowe, D. M., and Porter, R. R., 1972, Isolation and characterization of Clq, a subcomponent of the first component of complement, from human and rabbit sera, Biochem. J. 130: 749.PubMedGoogle Scholar
  213. Rosen, F. S., Charache, P., Pensky, J., and Donaldson, V., 1965, Hereditary angioneurotic edema. Two genetic variants, Science 148: 957.PubMedCrossRefGoogle Scholar
  214. Rosenfeld, S. I., Stapls, P., and Leddy, J., 1975, Angioedema and hypocomplementemia. Unusual feature of lymphoma, J. Allergy Clin. Immunol. 55: 104.Google Scholar
  215. Rosenfeld, S. I., Kelly, M. E., and Leddy, J. P., 1976, Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical and family studies, J. Clin. Invest. 57: 1626.PubMedCrossRefGoogle Scholar
  216. Ross, G. D., and Polley, M. J., 1975, Specificity of human lymphocyte complement receptors, J. Exp. Med. 141: 1163.PubMedCrossRefGoogle Scholar
  217. Rother, K., 1972, Leukocyte mobilizing factor: A new biological activity derived from the third component of complement, Eur. J. Immunol. 2: 550.PubMedCrossRefGoogle Scholar
  218. Ruddy, S., and Austen, K. F., 1969, C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell bound C3, J. Immunol. 102: 533.PubMedGoogle Scholar
  219. Ruddy, S., and Austen, K. F., 1971, C3b inactivator in man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b, J. Immunol. 107: 742.PubMedGoogle Scholar
  220. Ruddy, S., Gigli, I., Sheffer, A. L., and Austen, K. F., 1968, The laboratory diagnosis of hereditary angioedema, in: Proceedings of the 6th International Congress of Allergology, Montreal 1%7 (A. Knight et al.,eds.), Excerpta Medica International Congress Series No. 162, Amsterdam.Google Scholar
  221. Ruddy, S., Klemperer, M. R., Rosen, F. S., Austen, K. F., and Kumate, J., 1970, Hereditary deficiency of the second component of complement (C2) in man: Correlation of C2 haemolytic activity with immunochemical measurements of C2 protein, Immunology 18: 943.PubMedGoogle Scholar
  222. Russell, P. K., Intavivat, A., and Kanchanipilant, S., 1969, Anti-dengue immunoglobulins and serum ß1c/a globulin levels in dengue shock syndrome, J. Immunol. 102: 412.PubMedGoogle Scholar
  223. Rynes, R. I., Urizar, R. E., and Pickering, R. J., 1977, Genetic deficiency of the second component of complement (C2) associated with systemic lupus erythematosus, Am. J. Med. 63: 279.PubMedCrossRefGoogle Scholar
  224. Rynes, R. I., Urizar, R. E., and Pickering, R. J., 1978, Heterogeneity of the clinical syndrome in patients with systemic lupus erythematosus and genetic deficiency of the second component of complement, Clin. Exp. Immunol. 32: 59.PubMedGoogle Scholar
  225. Saitz, E. W., Dierks, R. E., and Shepard, C. C., 1968, Complement and the second component of complement in leprosy, Int. J. Lepr. 36: 400.Google Scholar
  226. Sakai, K., and Stroud, R. M., 1973, Purification, molecular properties, and activation of Cl proesterase, Clsl, J. Immunol. 110: 1010.Google Scholar
  227. Sams, W. M., Jr., 1974, Hypocomplementemia with cutaneous vasculitis and arthritis: A new syndrome, Arch. Dermatol. 110: 290.PubMedCrossRefGoogle Scholar
  228. Sams, W. M., Jr., Claman, H. N., Kohler, P. F., McIntosh, R. W., Small, P., and Mass, M. F., 1975, Human necrotizing vasculitis: Immunoglobulins and complement in vessel walls of cutaneous lesions and normal skin, J. Invest. Dermatol. 64: 441.PubMedCrossRefGoogle Scholar
  229. Sandberg, A. L., Götze, O., Müller-Eberhard, H. J., and Oster, A. G., 1971, Complement utilization by guinea pig Yl and Y2 immunoglobulins through the C3 activator system, J. Immunol. 107: 920.PubMedGoogle Scholar
  230. Sandberg, A. L., Wohl, S. M., and Mergenhagen, S. E., 1975, Lymphokine production by C36-stimulated B cells, J. Immunol. 115: 139.PubMedGoogle Scholar
  231. Scharfstein, J., Ferreira, A., Gigli, I., and Nussenzweig, V., 1978, Human C4-binding protein. I. Isolation and characterization, J. Exp. Med. 148: 207.PubMedCrossRefGoogle Scholar
  232. Scherer, R., and Braun-Falco, O., 1976, Alternative pathway complement activation: A possible mechanism inducing skin lesions in benign gonococcal sepsis, Br. J. Dermatol. 95: 303.Google Scholar
  233. Schorlemmer, H. U., and Allison, A. C., 1976, Effects of activated complement components on enzyme secretion by macrophages, Immunology 31: 781.PubMedGoogle Scholar
  234. Schrager, M. A., and Rothfield, N. F., 1977, Pathways of complement activation in chronic discoid lupus: Serologic and immunofluorescence studies, Arthritis Rheum. 20: 637.PubMedCrossRefGoogle Scholar
  235. Schreiber, A. D., Kaplan, A. P., and Austen, K. F., 1973, Inhibition by Cl INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin-generation, J. Clin. Invest. 52: 1402.PubMedCrossRefGoogle Scholar
  236. Schreiber, A. D., Sweiman, B., Atkins, P., Goldwein, F., Pietra, G., Atkinson, B., and Abdow, N. I., 1976, Acquired angioedema with lymphoproliferative disorder: Association of CT inhibitor deficiency with cellular abnormality, Blood 48: 567.PubMedGoogle Scholar
  237. Schreiber, R. D., and Müller-Eberhard, H. J., 1974, Fourth component of human complement. Description of a three polypeptide chain structure, J. Exp. Med. 140: 1324.PubMedCrossRefGoogle Scholar
  238. Schreiber, R. D., Götze, O., and Müller-Eberhard, H. J., 1976a, Nephritic factor and initiating factor C3/C5 convertases, Fed. Proc. 35: 253 (abstr.).Google Scholar
  239. Schreiber, R. D., Götze, O., and Müller-Eberhard, H. J., 19766, Nephritic factor: Its structure and function and its relationship to initiating factor of the alternative pathway, Scand. J. Immunol. 5: 705.Google Scholar
  240. Schreiber, R. D., Pangburn, M. K., Lesavre, P. H., and Müller-Eberhard, H. J., 1978, Initiation of the alternative pathway of complement: Recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins, Proc. Natl. Acad. Sci. USA 75: 3948.PubMedCrossRefGoogle Scholar
  241. Schroeter, A. L., Copeman, P. W. M., Jordan, R. E., Sams, W. M., Jr., and Winkelmann, R. K., 1971, Immunofluorescence of cutaneous vasculitis associated with systemic disease, Arch. Dermatol. 104: 254.PubMedCrossRefGoogle Scholar
  242. Schur, P. H., and Becker, E. L., 1963, Pepsin digestion of rabbit and sheep antibodies. The effect on complement fixation, J. Exp. Med. 118: 891.PubMedCrossRefGoogle Scholar
  243. Seery, U. L., and Müller-Eberhard, H. J., 1973, Binding of porphyrins to rabbit hemopexin and albumin, J. Biol. Chem. 248: 3796.PubMedGoogle Scholar
  244. Sequeira, M., and Nelson, R. A., 1961, Platelet agglutination by immune-complexes and its possible role in hypersensitivity, J. Immunol. 86: 516.Google Scholar
  245. Sheagren, J. N., Block, J. B., Trautman, J. R., and Wolff, S. M., 1969, Immunologic reactivity in patients with leprosy, Ann. Intern. Med. 70: 295.PubMedGoogle Scholar
  246. Sheffer, A. L., Craig, J. M., Willms-Kretschmer, K., Austen, K. F., and Rosen, F. S., 1971, Histopathological and ultrastructural observations on tissues from patients with hereditary angioneurotic edema, J. Allergy 47: 292.PubMedGoogle Scholar
  247. Shelton, E., Yonemasa, K., and Stroud, R. M., 1972, Ultrastructure of the human complement component, Clq, Proc. Natl. Acad. Sci. USA 69: 65.PubMedCrossRefGoogle Scholar
  248. Shevach, E. M., Herberman, R., Frank, M. M., and Green, I., 1972, Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines, J. Clin. Invest. 51: 1933.PubMedCrossRefGoogle Scholar
  249. Shikano, S., 1966, Ocular pathology of Behçet’s syndrome, in: International Symposium on Behçet’s Disease, p. 111, Rome.Google Scholar
  250. Shimada, K., Kogure, M., Kawashima, R., and Nishoka, K., 1974, Reduction of complement in Behçet’s disease and drug allergy, Med. Biol. 52: 234.PubMedGoogle Scholar
  251. Shin, H. S., and Mayer, M. M., 1968, The third component of guinea pig complement. II. Kinetic study of the reaction of EAC 42a with guinea pig C3, Biochemistry 7: 2997.PubMedCrossRefGoogle Scholar
  252. Shin, H. S., Gewurz, H., and Snyderman, R., 1969, Reaction of cobra venom factor with guinea pig complement and generation of an activity chemotactic for polymorphonuclear leukocytes, Proc. Soc. Exp. Biol. Med. 131: 203.PubMedGoogle Scholar
  253. Shiraishi, S., and Stroud, R. M., 1975, Cleavage products of C4b produced by enzymes in human serum, Immunochemistry 12: 935.PubMedCrossRefGoogle Scholar
  254. Sim, R. B., Porter, R. R., Reid, K. B. M., and Gigli, I., 1977, The structure and enzymatic activities of the Clr and C Is subcomponents of Cl, the first component of human serum complement, Biochem. J. 163: 219.PubMedGoogle Scholar
  255. Sissons, J. G. P., Peters, D. K., Gwyn Williams, D., and Boulton-Jones, M. J., 1974, Skin lesions, angio-oedema and hypocomplementaemia, Lancet 2: 1350.PubMedCrossRefGoogle Scholar
  256. Sissons, J. G. P., West, R. J., Fallows, J., Williams, D. G., Boucher, B. J., Amos, N., and Peters, D. K., 1976, The complement abnormalities of lipodystrophy, N. Engl. J. Med. 294: 461.PubMedCrossRefGoogle Scholar
  257. Snyderman, R., Gewurz, H., and Mergenhagen, S. E., 1968, Interactions of the complement system with endotoxic lipopolysaccharide generation of a factor chemotactic for polymorphonuclear leukocytes, J. Exp. Med. 128: 259.PubMedCrossRefGoogle Scholar
  258. Snyderman, R., Phillips, J. K., and Mergenhagen, S. E., 1970, Polymorphonuclear leukocyte chemotactic activity in rabbit and guinea pig serum treated with immune complexes. Evidence for C5a as the major chemotactic factor, Infect. Immunol. 1: 521.Google Scholar
  259. Snyderman, R., Pike, M. C., Szatalowicz, V., and Meadows, L. M., 1977, A familial deficiency of the fifth component of complement, Clin. Res. 25: 368.Google Scholar
  260. Soothill, J. F., and Harvey, B. A. M., 1976, Defective opsonization—a common immunity deficiency, Arch. Dis. Child. 51: 91.PubMedCrossRefGoogle Scholar
  261. Soter, N., Austen, K. F., and Gigli, I., 1974, Urticaria arthralgias as manifestation of necrotizing angiitis (vasculitis), J. Invest. Dermatol. 63: 483.Google Scholar
  262. Soter. N. A., Mihm, M. C., Gigli, I., Dvorak, H. F., and Austen, K. F., 1976, Two distinct cellular patterns in cutaneous necrotizing angiitis, J. Invest. Dermatol. 66: 344.PubMedCrossRefGoogle Scholar
  263. Soter, N., Mihm, M. C., Dvorak, H. F., and Austen, K. F., 1978, Cutaneous necrotizing vasculitis: A sequential analysis of the morphological alterations occurring after mast cell degranulation in a patient with a unique syndrome, Clin. Exp. Immunol. 32: 46.PubMedGoogle Scholar
  264. Siegelberg, H. L., and Götze, O., 1972, Conversion of C3 proactivator and activation of the alternate pathway of complement activation by different classes and subclasses of human immunoglobulin, Fed. Proc. 31: 2478.Google Scholar
  265. Spiro, R. G., 1967, Studies on the renal glomerular basement membrane. Preparation and chemical composition, J. Biol. Chem. 242: 1915.PubMedGoogle Scholar
  266. Spitzer, R. E., Vallota, E. H., Forristal, J., Sudora, E., Stitzel, A., Davis, N. C., and West, C. D., 1969, Serum C3 lytic system in patients with glomerulonephritis, Science 164: 436.PubMedCrossRefGoogle Scholar
  267. Stern, R., Fu, M. S., Fotino, M., Agnello, V., and Kunkel, H. G., 1976, Hereditary C2 deficiency association with skin lesions resembling the discoid lesions of systemic lupus erythematosus, Arthritis Rheum. 19: 517.PubMedCrossRefGoogle Scholar
  268. Stolfi, R. L., 1968, Immune lytic transformation: A state of irreversible damage generated as a result of the reaction of the eighth component in the guinea pig complement system, J. Immunol. 100: 46.PubMedGoogle Scholar
  269. Stroud, R. M., Mayer, M. M., Miller, J. A., and McKenzie, A. T., 1966, C2ad, an inactive derivative of C2 released during decay of EAC4,2a, Immunochemistry 3: 163.PubMedCrossRefGoogle Scholar
  270. Sussman, M., Jones, J. H., Almeida, J. D., and Lachmann, P. J., 1973, Deficiency of the second component of complement associated with anaphylactoid purpura and presence of mycoplasm in the serum, Clin. Exp. Immunol. 14: 531.PubMedGoogle Scholar
  271. Tagami, H., and Ofuji, S., 1977, Characterization of a leukotactic factor derived from psoriatic scale, Br. J. Dermatol. 97: 509.PubMedCrossRefGoogle Scholar
  272. Tamura, N., and Nelson, R. A., 1967, Three naturally occurring inhibitors of components of complement in guinea pig and rabbit serum, J. Immunol. 99: 582.PubMedGoogle Scholar
  273. Taranta, A., and Franklin, E. C., 1961, Complement fixation by antibody fragments, Science 134: 1981.PubMedCrossRefGoogle Scholar
  274. Tarantino, A., Anelli, A., Costino, A., DeVecchio, A., Monti, G., and Massaro, L., 1978, Serum complement in essential mixed cryoglobulinemia, Clin. Exp. Immunol. 32: 77.PubMedGoogle Scholar
  275. Theophilopoulos, A. N., Bokisch, V. A., and Dixon, F. J., 1974, Receptor for soluble C3 and C3b on human lymphoblastoid (Raji) cells: Properties and biological significance, J. Exp. Med. 139:669.Google Scholar
  276. Thompson, R. A., and White, R. H. R., 1973, Partial lipodystrophy and hypocomplementaemic nephritis, Lancet 2: 679.PubMedCrossRefGoogle Scholar
  277. Tobelem, G., Wautier, L. J., and Peltier, A. P., 1974, C2 deficiency, platelet aggregation reduction and Lob-stein’s disease in the same family, Biomed. Exp. 21: 190.Google Scholar
  278. Tomar, R. H., and Kolchins, D., 1972, Complement and coagulation: Serum i 1c/0 la in disseminated intravascular coagulation, Thromb. Diath. Haemorrh. 27: 389.PubMedGoogle Scholar
  279. Traub, W., and Piez, K. A., 1971, The chemistry and structure of collagen, Adv. Protein Chem. 25: 243.PubMedCrossRefGoogle Scholar
  280. Valet, G., and Cooper, N. R., 1974a, Isolation and characterization of the proenzyme form of the Cls subunit of the first complement component, J. Immunol. 122: 339.Google Scholar
  281. Valet, G., and Cooper, N. R., 1974b, Isolation of the proenzyme form of the Clr subunit of the first complement component, J. Immunol. 112: 1667.PubMedGoogle Scholar
  282. Vallota, E. H., Götze, O., Spiegelborg, H. H., Forriscal, J., West, D. C., and Müller-Eberhard, H. J., 1974, A serum factor in chronic hypocomplementemic nephritis distinct from immunoglobulin and activating the alternative pathway of complement, J. Exp. Med. 139: 1249.PubMedCrossRefGoogle Scholar
  283. Vogt, W., Schmidt, G., Von Buttlar, B., and Dieminger, L., 1978, A new function of the activated third component of complement: Binding to C5, an essential step for C5 activation, Immunology 34: 29.PubMedGoogle Scholar
  284. Wakefield, M. A., 1976, The interrelationship between hypocomplementaemia, partial lipodystrophy and mesangiocapillary glomerulonephritis, Postgrad. Med. J. 52: 651.PubMedCrossRefGoogle Scholar
  285. Weiler, J. M., Daha, M. R., Austen, K. F., and Fearon, D. T., 1976, Control of the amplification convertase of complement by the plasma protein 01H, Proc. Natl. Acad. Sci. USA 73: 3268.PubMedCrossRefGoogle Scholar
  286. Weiss, T. D., Tsai, Cheng, Baldassare, and Zuckner, J., 1978, Skin lesions in viral hepatitis: Histologic and immunofluorescent studies, Am. J. Med. 64: 269.PubMedCrossRefGoogle Scholar
  287. Wellek, B., and Opferkuch, W., 1975, A case of deficiency of the seventh component of complement in man: Biological properties of a C7-deficient serum and description of a C7-inactivating principle, Clin. Exp. Immunol. 19: 223.PubMedGoogle Scholar
  288. Wemanbu, S. N. C., Turk, J. L., Waters, M. F. R., and Rees, R. J. W., 1969, Erythema nodosum leprosum: A clinical manifestation of the Arthus phenomenon, Lancet 2: 933.CrossRefGoogle Scholar
  289. Whaley, K., and Ruddy, S., 1976a, Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivation, Science 193: 1011.PubMedCrossRefGoogle Scholar
  290. Whaley, K., and Ruddy, S., 1976b, Modulation of the alternative complement pathway by 01H globulin, J. Exp. Med. 144: 1147.PubMedCrossRefGoogle Scholar
  291. Wild, J., Zvaifler, N., Müller-Eberhard, H., and Wilson, C., 1974, Deficiency of the second component (C2) in a patient with discoid lupus erythematosus (DLE), J. Clin. Invest. 53: 84.Google Scholar
  292. Williams, C. A., and Chase, M. W., 1977, Methods in Immunology and Immunochemistry, Vol. 4, p. 127, Academic Press, New York.Google Scholar
  293. Williams, R. C., Jr., and Kunkel, H. G., 1992, Rheumatoid factor, complement, and conglutinin aberrations in patients with subacute bacterial endocarditis, J. Clin. Invest. 41: 666.CrossRefGoogle Scholar
  294. Wuepper, K. D., Bokisch, V. A., Müller-Eberhard, H. J., and Stoughton, R. B., 1972, Cutaneous response to human C3a anaphylatoxin in man, Clin. Exp. Immunol. 11: 13.PubMedGoogle Scholar
  295. Zeek, P. M., 1953, Periarteritis nodosa and other forms of necrotizing angiitis, N. Eng. J. Med. 248: 764.CrossRefGoogle Scholar
  296. Ziccardi, R. G., and Cooper, N. R., 1978, Modulation of the antigenicity of CTr and CTs by C f INH, J. Immunol. 121: 2148.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1981

Authors and Affiliations

  • Irma Gigli
    • 1
  1. 1.Department of Dermatology and MedicineNew York University Medical Center and Irvington House InstituteNew YorkUSA

Personalised recommendations